GlassScriptPhysician profile
Olga Farole
NPI 1316521073
$2,611.19
in general payments reported to CMS, 2019-2025
11 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $380 · 2023: $562 · 2024: $1,251 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827 · Travel and Lodging: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.39 |
| Travel and Lodging | $403.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $907.66 | 2024 | Vns Therapy |
| Sk Life Science, INC. | $520.53 | 2024-2025 | Xcopri |
| Abbvie INC. | $320.56 | 2022-2025 | |
| Pfizer INC. | $214.34 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $208.00 | 2022 | |
| Amgen INC. | $125.00 | 2022 | |
| Neurelis, INC. | $114.33 | 2024 | Valtoco |
| Ucb, INC. | $94.84 | 2025 | Fintepla |
| Alnylam Pharmaceuticals INC. | $56.41 | 2023 | Onpattro |
| Lundbeck LLC | $25.55 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.97 | 2023 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Farole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.